Table 1.
Baseline Characteristics, Study Treatment and OCT System, and Best-Corrected Visual Acuity at Baseline and Week 56
| Characteristic | Super Responders (n = 15) | Non–Super Responders (n = 66) |
|---|---|---|
| Female sex | 11 (73) | 40 (61) |
| Age (yrs) | 81 ± 8 | 77 ± 10 |
| Lesion type | ||
| Minimally classic | 5 (33) | 14 (21) |
| Occult | 7 (47) | 18 (27) |
| Predominantly classic | 3 (20) | 34 (52) |
| Presence of hyperreflective material | 10 (67) | 57 (86) |
| Presence of SRF | 13 (87) | 59 (89) |
| Presence of IRF | 13 (87) | 57 (86) |
| Study treatment | ||
| Brolucizumab | 8 (53) | 33 (50) |
| Aflibercept | 7 (47) | 33 (50) |
| OCT system | ||
| Cirrus | 4 (27) | 24 (36) |
| Spectralis | 11 (73) | 42 (64) |
| BCVA (ETDRS letters) | ||
| Baseline | 56.6 ± 9.0 | 55.1 ± 13.3 |
| Week | 62.5 ± 21.4 | 61.4 ± 19.7 |
BCVA = best-corrected visual acuity; IRF = intraretinal fluid; SRF = subretinal fluid.
Data are presented as no. (%) or mean standard deviation. Ocular-specific characteristics refer to the study eye.